Drug Trial Radar · NCT00656136
BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)
Last checked: Nov 19, 2026Latest source record: Jul 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
585
Actual
Start
Apr 2008
Primary completion
Oct 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Apr 10, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, double-blind, multi-center Phase IIb/III trial will be performed in patients with NSCLC who have received previous treatment with at least one but not more than two lines of cytotoxic chemotherapy (one line must have been a platinum-containing regimen) and either gefitinib or erlotinib for a period of at least 12 weeks and then progressed. The primary objective of this randomized trial is to determine the efficacy of BIBW 2992 as a single agent (Arm A) as compared to a matching placebo (Arm B) in this patient population. Patients on both treatment arms will receive best supportive care in addition to study treatment. Patients enrolled into the trial will be treated and followed until death or lost to follow-up.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
placeboDrug
Patients receive placebo once daily
BIBW 2992Drug
Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From randomization until death or the last patient out date, an average of 12 months
Locations
90 sites in 15 countries. Site status is shown where the registry gives one.
1200.23.038 Boehringer Ingelheim Investigational Site
Kingman, Arizona
1200.23.046 Boehringer Ingelheim Investigational Site
Fayetteville, Arkansas
1200.23.027 Boehringer Ingelheim Investigational Site
Anaheim, California
1200.23.028 Boehringer Ingelheim Investigational Site
Berkeley, California
1200.23.029 Boehringer Ingelheim Investigational Site
Modesto, California
1200.23.045 Boehringer Ingelheim Investigational Site
Montebello, California
1200.23.009 Boehringer Ingelheim Investigational Site
Orange, California
1200.23.026 Boehringer Ingelheim Investigational Site
Palm Springs, California
1200.23.024 Boehringer Ingelheim Investigational Site
North Miami Beach, Florida
1200.23.020 Boehringer Ingelheim Investigational Site
New York, New York
1200.23.013 Boehringer Ingelheim Investigational Site
Valhalla, New York
1200.23.056 Boehringer Ingelheim Investigational Site
Salt Lake City, Utah
1200.23.039 Boehringer Ingelheim Investigational Site
Renton, Washington
1200.23.050 Boehringer Ingelheim Investigational Site
Seattle, Washington
1200.23.32004 Boehringer Ingelheim Investigational Site
Edegem, Belgium
1200.23.32003 Boehringer Ingelheim Investigational Site
Ghent, Belgium
1200.23.32001 Boehringer Ingelheim Investigational Site
Leuven, Belgium
1200.23.32005 Boehringer Ingelheim Investigational Site
Liège, Belgium
1200.23.32006 Boehringer Ingelheim Investigational Site
Namur, Belgium
1200.23.1002 Boehringer Ingelheim Investigational Site
Edmonton, Alberta, Canada
1200.23.1005 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
1200.23.1009 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
1200.23.1001 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1200.23.1004 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1200.23.86001 Boehringer Ingelheim Investigational Site
Beijing, China
1200.23.86002 Boehringer Ingelheim Investigational Site
Beijing, China
1200.23.86003 Boehringer Ingelheim Investigational Site
Beijing, China
1200.23.86009 Boehringer Ingelheim Investigational Site
Chengdu, China
1200.23.86007 Boehringer Ingelheim Investigational Site
Guangzhou, China
1200.23.86008 Boehringer Ingelheim Investigational Site
Hangzhou, China
1200.23.86004 Boehringer Ingelheim Investigational Site
Shanghai, China
1200.23.86005 Boehringer Ingelheim Investigational Site
Shanghai, China
1200.23.86006 Boehringer Ingelheim Investigational Site
Shanghai, China
1200.23.3303A Boehringer Ingelheim Investigational Site
Besançon, France
1200.23.3303C Boehringer Ingelheim Investigational Site
Besançon, France
1200.23.3305A Boehringer Ingelheim Investigational Site
Caen, France
1200.23.3304A Boehringer Ingelheim Investigational Site
La Tronche, France
1200.23.3304B Boehringer Ingelheim Investigational Site
La Tronche, France
1200.23.3307A Boehringer Ingelheim Investigational Site
Lyon, France
1200.23.3301A Boehringer Ingelheim Investigational Site
Paris, France
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.